Karuna Therapeutics Inc.
- Address
- Route 206, Province Line Road
Sponsor Overview
Specializations
Schizophrenia
Clinical research in schizophrenia focuses on persistent symptom control, with attention to positive and negative symptoms and the management of inadequately controlled disease.
- Adjunctive treatment for schizophrenia
- PANSS-based symptom assessment
- Long-term safety and tolerability
The therapeutic emphasis includes ongoing evaluation of symptom burden in adults living with chronic psychotic illness.
Psychosis associated with Alzheimer’s disease
Research in psychosis associated with Alzheimer’s disease addresses neuropsychiatric symptoms such as hallucinations and delusions in the context of Alzheimer’s disease.
- Neuropsychiatric symptoms
- Hallucinations and delusions
- Alzheimer’s disease-related psychosis
Clinical interest extends to both symptom improvement and longer-term treatment tolerability in this neurodegenerative setting.
Long-term psychiatric safety
Several studies concentrate on extended treatment exposure, with a focus on safety, tolerability, and sustained use in psychiatric disorders.
- Extended treatment safety
- Tolerability over time
- Maintenance of clinical benefit
This area reflects continued monitoring of treatment experience in both schizophrenia and Alzheimer’s disease-related psychosis.
Neuropsychiatric symptom management
The sponsor’s research activity is centered on disorders involving psychosis and broader neuropsychiatric symptom domains, with particular attention to behavioral disturbances and perceptual abnormalities.
- Psychosis treatment
- Behavioral symptoms in Alzheimer’s disease
- Clinical efficacy in psychiatric illness
These studies align with therapeutic development in central nervous system disorders affecting cognition, perception, and behavior.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of KarXT Efficacy and Safety in Treating Psychosis Associated with Alzheimer's Disease: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study |  Belgium Greece Hungary Poland | Not Recruiting |
| Evaluation of the Efficacy and Safety of Adjunctive Trospium Chloride and Xanomeline Tartrate in Patients with Inadequately Controlled Schizophrenia Symptoms |  Bulgaria | Not Recruiting |
| Long-term Safety and Tolerability Assessment of Adjunctive Trospium Chloride and Xanomeline Tartrate in Patients with Inadequately Controlled Schizophrenia Symptoms | Bulgaria | Not Recruiting |
| Long-Term Safety and Tolerability Assessment of Trospium Chloride and Xanomeline Tartrate in Psychosis Associated with Alzheimer's Disease | Belgium Bulgaria Croatia Czechia France Germany Greece Hungary Italy Poland Portugal Romania Slovakia Spain | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 103 sites across their trial portfolio.
Therapeutic Focus
- 1.Mental Disorders3 trials150 other sponsors
- 2.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
103 centres- Address
- Ul. Rudolfa Weigla 5, 53-114 Wroclaw
- Address
- Gr. Lampraki 3, 54 636 Thessaloniki
- Address
- Sumavska 2, Vychodni Predmesti, 301 00 Pilsen
- Address
- Deltalaan 1, 8800 Roeselare
- Address
- President Kennedylaan 4, 8500 Kortrijk
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Karuna Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.